Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Prelude Therapeutics Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PRELUDE TO PRIORITIZE DEVELOPMENT OF MUTANT SELECTIVE JAK2V617F JH2 INHIBITOR AND KAT6A SELECTIVE DEGRADER PROGRAMS PAUSING FURTHER CLINICAL DEVELOPMENT OF SMARCA2 SELECTIVE DEGRADER PROGRAMS JAK2V617F OPTION AGREEMENT WITH INCYTE, AS PREVIOUSLY ANNOUNCED, INCLUDES UPFRONT PAYMENT OF $35 MILLION, A $25 MILLION EQUITY INVESTMENT AND $100 MILLION IF OPTION IS EXERCISED CUMULATIVE CAPITAL EXPECTED TO FUND PLANNED OPERATIONS INTO 2027 BASED ON THE COMPANY'S PRELIMINARY ESTIMATES, AND POTENTIALLY INTO THE THIRD QUARTER OF 2028 IF INCYTE EXERCISES OPTION ON JAK2 PROGRAM COMPANY TO RELEASE THIRD QUARTER 2025 FINANCIAL RESULTS AND CONDUCT AN INVESTOR CONFERENCE CALL ON NOVEMBER 12, 2025 WILMINGTON, DEL., NOV. 04, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD), A PRECISION ONCOLOGY COMPANY, TODAY IS PROVIDING A NUMBER OF STRATEGIC UPDATES, INCLUDING ITS RECENTLY EXECUTED OPTION AGREEMENT WITH INCYTE CORPORATION CENTERED ON ITS PREVIOUSLY UNDISCLOSED JAK2V617F MUTANT SELECTIVE INHIBITOR PROGRAM, PRIORITIZING DEVELOPMENT OF ITS FIRST-IN-CLASS KAT6A SELECTIVE DEGRADER PROGRAM AND PAUSING OF ITS SMARCA2 PROGRAMS.

PRELUDE THERAPEUTICS ANNOUNCESSTRATEGIC BUSINESS UPDATE

INCYTE SECURES AN EXCLUSIVE OPTION TO ACQUIRE PRELUDE'S MUTANT SELECTIVE JAK2V617F JH2 INHIBITOR PROGRAM MUTANT SELECTIVE JAK2V617F JH2 INHIBITORS HAVE DISEASE-MODIFYING POTENTIAL IN TREATING PATIENTS LIVING WITH MYELOPROLIFERATIVE NEOPLASMS (MPNS) PRELUDE TO RECEIVE A $35 MILLION UPFRONT PAYMENT AND $25 MILLION STRATEGIC EQUITY INVESTMENT, $100 MILLION IF INCYTE WERE TO EXERCISE THE OPTION TO ACQUIRE THE PROGRAM, AND UP TO $775 MILLION IN ADDITIONAL POTENTIAL MILESTONES PLUS ROYALTIES ON NET SALES PRELUDE WILL CONTINUE TO DEVELOP ALL JAK2V617F PROGRAM ASSETS DURING THE OPTION PERIOD; IF OPTIONED, INCYTE WOULD LEAD DEVELOPMENT AND COMMERCIALIZATION GLOBALLY WILMINGTON, DEL., NOV. 04, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ:PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, TODAY ANNOUNCED AN EXCLUSIVE OPTION AGREEMENT WITH INCYTE (NASDAQ:INCY) FOCUSED ON PRELUDE'S PREVIOUSLY UNDISCLOSED MUTANT SELECTIVE JAK2V617F JH2 INHIBITOR PROGRAM IN DEVELOPMENT FOR PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPNS).

PRELUDE THERAPEUTICS ANNOUNCES EXCLUSIVE OPTION AGREEMENT WITH INCYTE TO ADVANCE MUTANT SELECTIVE JAK2V617F JH2 INHIBITORS

WILMINGTON, DEL., NOV. 03, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD) (PRELUDE OR THE COMPANY), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, TODAY ANNOUNCED THE PUBLICATION OF TWO ABSTRACTS WITH PRECLINICAL DATA ON THE COMPANY'S JAK2V617F MUTANT SELECTIVE INHIBITORS AND CALR-TARGETED DEGRADER ANTIBODY CONJUGATES (DACS) DISCOVERY PROGRAM, BOTH ACCEPTED FOR ORAL PRESENTATION AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) 67TH ANNUAL MEETING TAKING PLACE IN ORLANDO, FL DECEMBER 6-9, 2025. THE ABSTRACTS CAN BE FOUND ON THE ASH 2025 WEBSITE ASH ANNUAL MEETING & EXPOSITION - HEMATOLOGY.ORG .

PRELUDE THERAPEUTICS ANNOUNCES PUBLICATION OF ABSTRACTS FOR PRESENTATION AT THE AMERICAN SOCIETY OF HEMATOLOGY 67TH ANNUAL MEETING

WILMINGTON, DEL., OCT. 17, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF KATINA DORTON TO ITS BOARD OF DIRECTORS, EFFECTIVE TODAY. MS. DORTON HAS MORE THAN 30 YEARS OF INDUSTRY EXPERTISE AND LEADERSHIP IN HEALTHCARE AND LIFE SCIENCES INCLUDING SERVICE ON SEVERAL BOARDS OF PUBLIC LIFE SCIENCE COMPANIES, EXECUTIVE FINANCIAL LEADERSHIP AND INVESTMENT BANKING.

PRELUDE THERAPEUTICS ANNOUNCES APPOINTMENT OF KATINA DORTON, J.D., MBA TO ITS BOARD OF DIRECTORS

PRT7732, ONCE DAILY ORAL SMARCA2 DEGRADER, CURRENTLY ENROLLING AT THE SEVENTH DOSING COHORT (125 MG); COMPANY TO PROVIDE AN UPDATE WITH PRELIMINARY CLINICAL DATA, INCLUDING PK/PD, SAFETY AND INITIAL CLINICAL ACTIVITY BY YEAR END 2025 PHASE 1 STUDY OF PRT3789, A ONCE WEEKLY IV SMARCA2 DEGRADER, HAS BEEN COMPLETED; COMPANY TO PROVIDE FINAL DATA BY YEAR END 2025 PRELUDE IS ADVANCING A DEVELOPMENT CANDIDATE FOR ITS ORAL KAT6A DEGRADER PROGRAM AND REMAINS ON TRACK TO FILE AN IND IN THE FIRST HALF OF 2026 CURRENT CASH RUNWAY INTO THE SECOND QUARTER OF 2026 WITH $77.3 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES AS OF JUNE 30, 2025 WILMINGTON, DEL., AUG. 14, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED AN UPDATE ON ITS CLINICAL DEVELOPMENT PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

PRELUDE THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WILMINGTON, DEL., JUNE 02, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, ANNOUNCED TODAY THAT THE COMPANY WILL PARTICIPATE IN TWO UPCOMING HEALTHCARE CONFERENCES IN JUNE.

PRELUDE THERAPEUTICS TO PARTICIPATE IN UPCOMING HEALTHCARE CONFERENCES

PRT3789 MONOTHERAPY AND COMBINATION WITH DOCETAXEL ESCALATION ENROLLMENT IS COMPLETE AND THE COMPANY PLANS TO PRESENT UPDATED RESULTS IN THE SECOND HALF OF 2025 ENROLLMENT OF THE PHASE 1 STUDY OF PRELUDE'S ONCE DAILY, ORAL SMARCA2 DEGRADER, PRT7732 IS ADVANCING RAPIDLY, AND AN INITIAL DATA UPDATE IS ANTICIPATED IN THE SECOND HALF OF 2025 CURRENT CASH RUNWAY INTO THE SECOND QUARTER OF 2026 WITH $103.1 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES AS OF MARCH 31, 2025 WILMINGTON, DEL., MAY 06, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, TODAY REPORTED ITS FINANCIAL RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED AN UPDATE ON ITS CLINICAL DEVELOPMENT PIPELINE AND OTHER CORPORATE DEVELOPMENTS.

PRELUDE THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WILMINGTON, DEL., MAY 01, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, ANNOUNCED TODAY THAT THE COMPANY WILL PARTICIPATE IN THE CITIZENS LIFE SCIENCES CONFERENCE TAKING PLACE IN NEW YORK ON MAY 7, 2025.

PRELUDE THERAPEUTICS TO PARTICIPATE IN CITIZENS LIFE SCIENCES CONFERENCE

PRECLINICAL DATA ELUCIDATING THE MECHANISM OF ACTION OF PRT3789, PRELUDE'S FIRST-IN-CLASS, HIGHLY SELECTIVE SMARCA2 DEGRADER CURRENTLY IN EARLY CLINICAL DEVELOPMENT

PRELUDE ANNOUNCES PRESENTATIONS AT 2025 AACR ANNUAL MEETING

PRT3789 HAS DEMONSTRATED CLINICAL PROOF-OF-CONCEPT THAT SELECTIVELY DEGRADING SMARCA2 IS GENERALLY SAFE AND HAS MONOTHERAPY ANTI-TUMOR ACTIVITY IN PATIENTS WITH SMARCA4-DEFICIENT, NON-SMALL CELL LUNG (NSCLC), GASTRIC AND ESOPHAGEAL CANCER

PRELUDE THERAPEUTICS REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES PROGRAM OUTLOOK FOR 2025

WILMINGTON, DEL., MARCH 05, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, ANNOUNCED TODAY THAT THE COMPANY WILL PARTICIPATE IN THE BARCLAYS 27TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, TAKING PLACE IN MIAMI, FL ON MARCH 11, 2025.

PRELUDE THERAPEUTICS TO PARTICIPATE IN BARCLAYS 27TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

 PRT2527 DEMONSTRATED ACTIVITY ACROSS A RANGE OF RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES, INCLUDING PATIENTS WHO RECEIVED PRIOR CAR-T THERAPY

PRELUDE THERAPEUTICS PRESENTS PRELIMINARY RESULTS OF PHASE 1 DOSE-ESCALATION STUDY OF PRT2527 AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES

WILMINGTON, DEL., NOV. 27, 2024 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NASDAQ: PRLD), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, ANNOUNCED TODAY THAT THE COMPANY WILL PARTICIPATE IN THE CITIZENS JMP SECURITIES HEMATOLOGY AND ONCOLOGY SUMMIT, TAKING PLACE VIRTUALLY ON DECEMBER 2, 2024.

Prelude Therapeutics Incorporated

PRLD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Prelude Therapeutics Incorporated

PRLD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

PRLD